LONDON, June 26, 2017 -- Richard Veal joins the company with an impressive background in big pharma consulting, having previously been Director of Strategic Planning within leading healthcare communications firm Sudler & Hennessey. Prior to this, Veal was Vice-President at creative healthcare agency Digitas Health, where he was responsible for practice leadership across a portfolio of solid and blood cancer products spanning global and US markets.
In his new role, Veal will lead on Pharma Consulting’s solutions across all of its arms, from R&D strategy and commercial optimization, to portfolio management. He will also be spearheading the development of tailored, long-term business strategies for global clients including big pharma, mid-tier, generics and biotech organizations.
Veal has specialized knowledge of the oncology market and a wealth of experience in developing brand strategy, as well as pipeline, franchise and disease state planning, having worked with both global pharmaceutical giants and life science focused organizations.
He also brings new strategic and consultancy capabilities to Pharma Consulting, particularly around war gaming, brand positioning, strategic planning and executive workshops.
Tim Polack, Head of Consulting for Informa Business Intelligence, said: “With his expertise across an impressively broad range of specialisms, Richard will be incredibly valuable to the business. We pride ourselves on developing truly personalized solutions for our clients and Richard has a proven track-record when it comes to understanding a brand and advising on its position in the market. He is certainly the right man for the job.”
Commenting on his appointment, Veal said: “The company’s ambition is clear – to improve the strategic capabilities of the pharmaceutical industry as a whole. Its data-driven methods and use of business intelligence to inform company and market strategy is an innovative and effective approach, and is already making a significant impact for many global organizations.”
“Our vision is to be a true strategic partner to our customers,” commented Linda Blackerby, President of Informa Pharma Intelligence. “Our Pharma Consulting team, led by Richard, is poised to help our customers drive strategic innovations in the pharmaceutical industry, with the ultimate goal of improving healthcare outcomes.”
“This vision is one that I deeply share,” said Veal, “and I look forward to building on the success that Informa Pharma Consulting has already had in the industry.”
About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products - Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivio – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.
With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.
About Pharma Consulting
Pharma Consulting’s team of experts leverage Informa’s unique data and insights to provide customized analysis and strategic advice for pharmaceutical clients across the globe. For more information visit pharmaintelligence.informa.com/pharmaconsulting.
Contact: Tim Polack Head of Consulting Tel: +44 (020) 701 75370 Email: [email protected]


Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
First Western Ship Transits Strait of Hormuz Since Iran War Began
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 



